The University of Texas Health Science Center at San Antonio
8 clinical trials · 8 recruiting · OTHER
Trials by The University of Texas Health Science Center at San Antonio
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended...
Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer
This protocol is a single-institution feasibility study to identify the molecular and epidemiological risk factors in the development of gastric cancer in high-risk predominantly...
Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms
Participants will be asked to participate in this research study of a device that creates transcranial direct current stimulation (tDCS). The researchers hope to learn if 30...
Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
This study is being done to understand how reducing blood flow (BRT) during balance-challenging strengthening exercises (instability resistance training, or IRT) can help improve...
Behavioral Insomnia Treatment in Mild Traumatic Brain Injury
This is a single site, two-armed random controlled trials (RCT) comparing six sessions of Cognitive Behavioral Therapy for Insomnia (CBT-I) with four sessions of Brief Behavioral...
Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
The researchers hope to find out effects of transcranial direct current stimulation (tDCS) sessions on the behavioral symptoms of Huntington's Disease. If participants are...
Dapagliflozin Plus Pioglitazone in T1DM
Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients...
Dupilumab Effects Against Aeroallergen Challenge
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.